Shots:

• The companies collaborated to develop, commercialize & regulatory approval of Guardant360 CDx blood test for ESR1-mutated metastatic breast cancer
• The collaboration will use Guardant360 CDx assay, a ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to 1L therapy progression in the P-III trial (SERENA-6) evaluating camizestrant (selective estrogen receptor degrader + CDK4/6 inhibitors vs aromatase inhibitors + CDK4/6 inhibitors for HR+, HER2- metastatic breast cancer
• Guardant Health’s multiple tests were available for advanced & early-stage cancer patients & screening portfolio, incl. Shield test used for eligible patients for cancer screening

Ref: Guardant Health | Image: Guardant Health